COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Tethered Capsule Endoscope in Screening Patients With Barrett Esophagus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02729948
Recruitment Status : Completed
First Posted : April 6, 2016
Last Update Posted : January 23, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Washington

Brief Summary:
This pilot clinical trial studies how well tethered capsule endoscope works in screening patients with Barrett esophagus (BE), a condition where the lining of the esophagus has changed or has been replaced with abnormal cells that may lead to cancer also called esophageal cancer. In an attempt to prevent the progression from BE to esophageal cancer, patients undergo a standard procedure called esophagogastroduodenoscopy (EGD) where patients are sedated and the doctor uses an endoscope to examine the tissue in the esophagus. Tethered capsule endoscope is a tiny capsule with a laser scan inside and a very thin cord attached to it. Patients swallow the capsule and the thin cord keeps the capsule in specific area in the esophagus. After pictures of the lining of esophagus are taken, the capsule is removed using the thin cord. Tethered capsule endoscope may be able to identify tissue changes in patients with BE without the need for sedation or anesthesia, thus eliminating the associated risks and costs associated with EGD.

Condition or disease Intervention/treatment Phase
Barrett Esophagus Other: Survey Administration Device: Tethered Capsule Endoscope Not Applicable

Detailed Description:


I. Evaluate image quality and usability of the tethered capsule endoscope after repeated clinical use and reprocessing.

II. Evaluate safety issues associated with the use of the device for this subject population - was there any noticeable difference from prior study of subjects at high risk of Barrett's esophagus using the same device, but without reprocessing.


I. Study other specified device characteristics or device application considerations.

II. Obtain preliminary data for use in designing a subsequent pivotal study of the device.


Patients swallow the tethered capsule endoscope (TCE) and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Use of a Tethered Capsule Endoscope in Screening for Barrett's Esophagus
Actual Study Start Date : July 28, 2016
Actual Primary Completion Date : August 3, 2017
Actual Study Completion Date : August 3, 2017

Arm Intervention/treatment
Experimental: Screening (TCE)
Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
Other: Survey Administration
Ancillary studies

Device: Tethered Capsule Endoscope
Undergo TCE
Other Name: TCE

Primary Outcome Measures :
  1. Consistent image quality [ Time Frame: At the conclusion of TCE exam (day 1) ]
    Consistent image quality defined as no significant degradation of lateral spatial resolution [line pairs per mm] and axial depth of focus [mm], maximum field of view [degrees cone angle], and color fidelity [qualitatively matches color chart] when measured after use in the clinic using color and resolution test targets and a test chamber to measure field of view. The standard care EGD will be digitally recorded to allow for review and comparison to the TCE procedure by a blinded, expert endoscopist.

  2. Consistent usability defined as no significant change to the tolerance rating given by the patient by survey, and ease of use by the physician by survey, and time for completing the examination [ Time Frame: At the conclusion of TCE exam (day 1) ]
  3. Incidence of adverse events associated with TCE use [ Time Frame: Up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability and willingness to provide written informed consent
  • Scheduled for endoscopic screening and/or evaluation of Barrett's esophagus

Exclusion Criteria:

  • Previous history of a swallowing disorder, such as scleroderma, achalasia, esophageal stricture or esophageal diverticulum
  • Symptoms of dysphagia
  • Suspicion or known history of gastrointestinal obstruction
  • History of prior surgery on the oropharynx, neck, esophagus, or stomach
  • Current diagnosis of cancer, unstable cardiovascular disease, end-stage liver or kidney disease, or other major medical illness
  • Currently taking anticoagulant medications or clopidogrel
  • Major physical disability which would prevent subject from transferring from a chair to a bed and sitting in an upright position
  • Inability to abstain from taking anything by mouth for at least 6 hours
  • Currently pregnant
  • Expected to undergo magnetic resonance imaging (MRI) within two weeks following the study procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02729948

Layout table for location information
United States, Washington
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109
Sponsors and Collaborators
University of Washington
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Michael Saunders Fred Hutch/University of Washington Cancer Consortium
Layout table for additonal information
Responsible Party: University of Washington Identifier: NCT02729948    
Other Study ID Numbers: 9561
NCI-2016-00112 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
9561 ( Other Identifier: Fred Hutch/University of Washington Cancer Consortium )
P30CA015704 ( U.S. NIH Grant/Contract )
First Posted: April 6, 2016    Key Record Dates
Last Update Posted: January 23, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Barrett Esophagus
Precancerous Conditions
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases